tirzepatide molecule structure CAS-no-2023788-19-2 Tirzepatide, a New Era of

Clinical studies reported average weight reduction of approximately 17%, with some participants achieving 20% or greater weight loss

(1) Overview BPC-157 has been steadily researched for its potential in wound healing

Now, lets make that more practical

Once the results from the Phase 2 clinical trial investigating Retatrutide in obese people were made public in June 2023, I KNEW the entire biohacking industry would see it as a coveted treasure

In addition, some GLP-1 drugs have gotten additional FDA approvals for reduction of cardiovascular disease risk and treatment of sleep apnea and fatty liver disease (also called MASHLD and AFLD) in people with overweight or obesity

Semaglutide mimics the GLP-1 hormone, signalling fullness to your brain, while phentermine stimulates your central nervous system, reducing appetite [2]